|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500098513 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-10 14:21:39 |
|
注册时间: Date of Registration: |
2025-03-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
芬太尼联合布比卡因腰麻用于剖宫产术对母婴血液药物代谢的研究 |
|
Public title: |
Study on the effect of fentanyl combined with bupivacaine spinal anesthesia on maternal and infant blood drug metabolism in cesarean section |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
芬太尼联合布比卡因腰麻用于剖宫产术对母婴血液药物代谢的研究 |
|
Scientific title: |
Study on the effect of fentanyl combined with bupivacaine spinal anesthesia on maternal and infant blood drug metabolism in cesarean section |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
马伟强 |
研究负责人: |
马伟强 |
|
Applicant: |
Weiqiang Ma |
Study leader: |
Weiqiang Ma |
|
申请注册联系人电话: Applicant telephone: |
+86 182 9530 0221 |
研究负责人电话:
Study leader's |
+86 173 9505 5188 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
410647137@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
yeqingshan@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
银川市金凤区正源北街301号 |
研究负责人通讯地址: |
银川市金凤区正源北街301号 |
|
Applicant address: |
301 Zhengyuan North Street, Jinfeng District, Yinchuan |
Study leader's address: |
301 Zhengyuan North Street, Jinfeng District, Yinchuan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
宁夏回族自治区人民医院 |
||
|
Applicant's institution: |
Ningxia Hui Autonomous Region People's Hospital |
||
|
研究负责人所在单位: |
宁夏回族自治区人民医院 |
||
|
Affiliation of the Leader: |
Ningxia Hui Autonomous Region People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理[2025]-LL-006 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
宁夏回族自治区人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the People's Hospital of Ningxia Hui Autonomous Region |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-02-05 00:00:00 | ||
|
伦理委员会联系人: |
魏景坤 |
||
|
Contact Name of the ethic committee: |
Jingkun Wei |
||
|
伦理委员会联系地址: |
银川市金凤区正源北街301号 |
||
|
Contact Address of the ethic committee: |
301 Zhengyuan North Street, Jinfeng District, Yinchuan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 182 9501 9369 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
宁夏回族自治区人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ningxia Hui Autonomous Region People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
银川市金凤区正源北街301号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
301 Zhengyuan North Street, Jinfeng District, Yinchuan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
医院或自费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hospital or at one's own expense |
||||||||||||||||||||||
|
研究疾病: |
无 |
||||||||||||||||||||||
|
Target disease: |
None |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
采用高效液相-质谱仪(QSight 420MD)测定剖宫产术腰麻芬太尼联合布比卡因母婴血液中芬太尼的浓度,明确芬太尼和布比卡因在腰麻下对妊娠期产妇剖宫产术中母婴血液浓度的特点,为临床合理使用芬太尼提供参考依据,降低母婴并发症,为临床芬太尼的使用提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To determine the blood concentration of fentanyl in mothers and infants during cesarean section under spinal anesthesia with fentanyl combined with bupivacaine by high performance liquid chromatography-mass spectrometer (QSight 420MD), and to clarify the characteristics of blood concentration of fentanyl and bupivacaine in pregnant women and infants during cesarean section under spinal anesthesia, so as to provide reference for clinical rational use of fentanyl and reduce maternal and infant complications. To provide a basis for the clinical use of fentanyl. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)拟行剖宫产的产妇; (2)ASA分级II;单胎;年龄:25-35岁;体重70-90kg; (3)自愿参加本研究,签署知情同意书,经本医院伦理委员会批准。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Women undergoing cesarean section; (2) ASA grade II; Singleton pregnancy; Age: 25-35 years old; Body weight 70-90kg; (3) Voluntarily participated in this study and signed the informed consent form, which was approved by the ethics committee of our hospital. |
||||||||||||||||||||||
|
排除标准: |
(1)多胎妊娠; (2)存在腰麻相关禁忌症; (3)产妇存在严重心肺功能不全及产科相关并发症(如妊娠合并高血压疾病、妊娠合并糖尿病、孕产妇先天性心脏病、胎盘早剥、胎儿窘迫、前置胎盘等); (4)存在特殊感染性疾病,药物滥用史,精神病史; (5)患者拒绝参加研究。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Multiple pregnancy; (2) The presence of spinal anesthesia related contraindications; (3) Maternal severe cardiopulmonary dysfunction and obstetric complications (such as pregnancy complicated with hypertensive disease, pregnancy complicated with diabetes, maternal congenital heart disease, placental abruption, fetal distress, placenta previa, etc.); (4) History of special infectious diseases, drug abuse, and mental illness; (5) The patient refused to participate in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-30 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-04-01 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026年9月,在http://www.medresman.org.cn/公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In September 2026, it will be released in http://www.medresman.org.cn/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:病例记录表,数据管理:EXCEL表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: case record table; data management: EXCEL table |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |